Hepatitis C

Findings showed Fatty Liver Index was predictive of cardiovascular disease mortality among patients with a history of myocardial infarction.

The discontinuation of LIMT-2 was announced after 4 patients experienced hepatobiliary events resulting in liver decompensation during the phase 3 study of peginterferon lambda for HDV.

Investigators noted improved liver function, increased prevalence of anemia, and decreased hemoglobin concentration, hematocrit index, and estimated glomerular filtration rate among patients with HCV after 12 weeks of DAA treatment.

Results from RESPONSE show seladelpar may improve measures of disease activity and reduce symptom burden in patients with PBC.

The University of Miami study previews the upcoming phase 3 trial and what the investigative seladelpar may provide patients with primary biliary cholangitis.

The phase 3 seladelpar investigator discusses the current landscape of care available for patients with PBC.

The clinical trial compared outcomes in patients with NAFLD on a resistant starch diet to a control group over a 4-month period, with results suggesting microbiota dietary supplements may improve liver conditions.

A number of innovative, virus-targeting agents are under investigation to treat HCV—or even prevent it.

Results from the retrospective cohort study indicated viral eradication with DAAs after liver transplantation improved liver function and patient survival after a long-term follow-up, even in cirrhotic patients.

Hypertension prevalence was significantly higher among adults with obesity and severe NAFLD, providing important information related to the association between hypertension and NAFLD severity.

A systematic review shows the muscle relaxant therapy is the lone intervention to benefit outcomes for the liver diseases among patients with alcohol use disorder, per randomized trials.

Diagnostic survey results indicated 62.7% of participating patients with hepatitis C expressed a low level of satisfaction with life.

Investigators identified a strong magnitude of association between MAFLD and risk of CKD based on the results of a comprehensive meta-analysis.

An analysis into correlation between COVID-19 vaccine uptake and that of more established vaccines showed research is lacking—yet troubling all the same.

Data support the benefit of bariatric surgery in patients at high risk of pancreatic ductal adenocarcinoma due to BMI and metabolic comorbidities.

Investigators find that while general hospitalizations decreased in 2020, hospitalizations due to alcohol-associated hepatitis increased by 16%.

Qazi reviews an analysis of an EHR-assisted smoking cessation module that could improve conversations between specialists and patients.

New 12-week data shows an investigative oral drug provided significant benefit in key outcomes associated with NASH disease relief.

An analysis of postmenopausal women shows a nearly two-fold increase in liver cancer incidence among those who consume at least 1 soft drink or fruit drink daily.

Approximately 1 in 5 newly diagnosed patients are initiating direct acting antivirals within 6 months, according to Medicaid data review.

A multinational study shows people who achieve sustained virologic response still face a 3-fold greater risk or more of mortality due to liver disease or drug-related issues.

Global estimate prevalence data suggest the virus affects more than 3% of the population, with available treatment and vaccination strategies used too infrequently.

New cross-sectional data show the sex gap in alcohol-related mortality has been narrowing since 1999, as women have become more susceptible to alcohol use and related diseases.

Skyrocketing rates of HCV have aligned with the opioid epidemic—and evidence the need for universal pregnancy screenings.

Though many countries established guidelines and strategies to eliminate the virus by 2030, the region is still behind on newborn virus management.